EMEA-002957-PIP02-21
Key facts
| Active substance |
Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide
|
| Therapeutic area |
Ophthalmology
|
| Decision number |
P/0437/2021
|
| PIP number |
EMEA-002957-PIP02-21
|
| Pharmaceutical form(s) |
Powder and solvent for solution for injection
|
| Condition(s) / indication(s) |
Treatment of diabetic retinopathy
|
| Route(s) of administration |
Intravitreal use
|
| Contact for public enquiries |
Boehringer Ingelheim International GmbH
E-mail: COMMSPaediatrics@boehringer-ingelheim.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|